| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9aa4d7ac4628b72dd48dd67f6a436fc9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d7e2f8fb5650d7d3616661464b67771 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2019-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5148a3ffa3350ad0e8b30fb8756f89b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce199d224750a6cee82d6e45eecbc645
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_856df191352f5596683eb7e65c061797
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc68936cfda0eb816642eae86d4b3c4f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4aed86d075142239c8338d41db6aa601
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_249d257b0cf65fa0383bbad47fb3a3da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83ea89b42c8a516d4b731e1e526e6042 |
| publicationDate |
2020-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020125640-A1 |
| titleOfInvention |
Estrogen receptor antagonist |
| abstract |
Provided is an indole compound. In particular, disclosed are a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof and a use of the same as an estrogen receptor antagonist in preparing a drug for treating estrogen receptor-positive breast cancer. <img file="55081dest_path_image002.jpg" he="75.94" img-content="drawing" img-format="jpg" inline="yes" orientation="portrait" wi="108.74"/> |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022143907-A1 |
| priorityDate |
2018-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |